By ADAM STEWART
After being diagnosed with Parkinson’s disease more than two years ago, Steve Quam of Anderson, S.C., discovered that exercise helped him limit his tremors.
Bicycling is one of his favorite exercises, so 64-year-old Quam decided he would ride across the U.S. to raise awareness of the disease. He began in Washington state and arrived Monday in Marion. He planned to finish his ride in South Carolina, probably mid-November.
Parkinson’s disease is a progressive disease that impairs motor skills, speech, and other functions. No cure has been found in the 200 years since it was discovered, Quam said.
But treatment is available. Quam said he couldn’t make the ride if he weren’t taking medication to suppress his temors.
He is riding in support of the Davis Phinney Foundation For Parkinson’s. Phinney was a great cyclist in the 1980s who competed in the Olympics and Tour de France. Phinney was diagnosed with Parkinson’s at age 40 and started his foundation to research the disease and provide support for patients.
Quam said he admired Phinney long before he knew of their connection.
The message he wants to spread with his ride is that people with Parkinson’s disease don’t have to stop doing things.
“You may have limitations, but with adjustments you can still do things you enjoy,” Quam said.
He had ridden about 2,600 miles of the 4,000-mile trip when he arrived in Marion. He has ridden between 30 and 60 miles most days, but his longest ride was 79 miles. His route from Washington to Kansas wasn’t direct, he said.
“I took the scenic tour,” through parts of British Columbia and Yellowstone and Glacier national parks, he said.
He also stopped in Boulder, Colo., where he had dinner with Phinney. Quam said his favorite part of the trip has been meeting other Parkinson’s disease patients and discussing what works for them to control their symptoms.
He is looking forward to seeing relatives in Missouri and his son in Memphis, Tenn.
For more information, go to http://sqpd.us or e-mail PedalForParkinsons@charter.net.
Monday, September 20, 2010
Sunday, September 19, 2010
Novel molecular pathway underlying Parkinson's disease identified
Researchers have identified a new molecular pathway underlying Parkinson’s disease and also pointed to existing drugs which may be able to slow progression of the disease.
The pathway involved proteins — known as polyamines — that were found to be responsible for the increase in build-up of other toxic proteins in neurons, which causes the neurons to malfunction and, eventually, die.
Though high levels of polyamines have been found previously in patients with Parkinson’s, the new study led by researchers at Columbia University Medical Centre is the first to identify a mechanism for why polyamines are elevated in the first place and how polyamines mediate the disease. The researchers also demonstrated in a mouse model of Parkinson’s disease that polyamine-lowering drugs had a protective effect.
“The most exciting thing about the finding is that it opens up the possibility of using a whole class of drugs that is already available,” said Scott A. Small, senior author of the study.
“Additionally, since polyamines can be found in blood and spinal fluid, this may lead to a test that could be used for early detection of Parkinson’s,” he said.
Though many cellular defects have been found to cause rare, inherited forms of Parkinson’s disease, most cases of Parkinson’s are caused by unknown changes inside the brain’s neurons.
The researchers used a wide variety of scientific techniques to search for still unidentified defects in the brain.
The success of the technique depends on identifying regions of the brain affected by the disease and comparing them to unaffected regions.
Using high-resolution functional magnetic resonance imaging (fMRI), Nicole Lewandowski, identified such regions in the brainstem of patients with Parkinson’s.
The scans showed that one region of the brainstem was consistently less active in these patients than in healthy control subjects. Also revealed in the scans was a neighbouring region that was unaffected by the disease.
Next, using brain tissue from deceased patients with Parkinson’s, the researchers looked for proteins that could potentially explain the brainstem imaging differences. To validate the finding, three separate studies — in yeast, mice, and people — were performed.
The yeast studies revealed that polyamines promote the accumulation of a toxic Parkinson’s-causing protein in living cells, and not just in test tubes, as was known from previous research.
In the mice studies, a link was established among SAT1, polyamines, and Parkinson’s toxins in a mammalian brain. These experiments also revealed that drugs that target SAT1 may be able to slow down the progression of Parkinson’s disease.
Genetic studies in patients with Parkinson’s provided further evidence that polyamines may help drive Parkinson’s disease in people. After examining the SAT1 gene in nearly 100 patients with Parkinson’s, it was uncovered that novel genetic variant that was found exclusively in the study’s patients with Parkinson’s but not in controls.
“Even though the variant was rare in patients with Parkinson’s, finding it was surprising and further strengthens the possibility that defects in the polyamine pathway help to trigger the disease,” said Small. The findings appeared in the Proceedings of the National Academy of Sciences.
http://www.thehindu.com/sci-tech/science/article642862.ece
The pathway involved proteins — known as polyamines — that were found to be responsible for the increase in build-up of other toxic proteins in neurons, which causes the neurons to malfunction and, eventually, die.
Though high levels of polyamines have been found previously in patients with Parkinson’s, the new study led by researchers at Columbia University Medical Centre is the first to identify a mechanism for why polyamines are elevated in the first place and how polyamines mediate the disease. The researchers also demonstrated in a mouse model of Parkinson’s disease that polyamine-lowering drugs had a protective effect.
“The most exciting thing about the finding is that it opens up the possibility of using a whole class of drugs that is already available,” said Scott A. Small, senior author of the study.
“Additionally, since polyamines can be found in blood and spinal fluid, this may lead to a test that could be used for early detection of Parkinson’s,” he said.
Though many cellular defects have been found to cause rare, inherited forms of Parkinson’s disease, most cases of Parkinson’s are caused by unknown changes inside the brain’s neurons.
The researchers used a wide variety of scientific techniques to search for still unidentified defects in the brain.
The success of the technique depends on identifying regions of the brain affected by the disease and comparing them to unaffected regions.
Using high-resolution functional magnetic resonance imaging (fMRI), Nicole Lewandowski, identified such regions in the brainstem of patients with Parkinson’s.
The scans showed that one region of the brainstem was consistently less active in these patients than in healthy control subjects. Also revealed in the scans was a neighbouring region that was unaffected by the disease.
Next, using brain tissue from deceased patients with Parkinson’s, the researchers looked for proteins that could potentially explain the brainstem imaging differences. To validate the finding, three separate studies — in yeast, mice, and people — were performed.
The yeast studies revealed that polyamines promote the accumulation of a toxic Parkinson’s-causing protein in living cells, and not just in test tubes, as was known from previous research.
In the mice studies, a link was established among SAT1, polyamines, and Parkinson’s toxins in a mammalian brain. These experiments also revealed that drugs that target SAT1 may be able to slow down the progression of Parkinson’s disease.
Genetic studies in patients with Parkinson’s provided further evidence that polyamines may help drive Parkinson’s disease in people. After examining the SAT1 gene in nearly 100 patients with Parkinson’s, it was uncovered that novel genetic variant that was found exclusively in the study’s patients with Parkinson’s but not in controls.
“Even though the variant was rare in patients with Parkinson’s, finding it was surprising and further strengthens the possibility that defects in the polyamine pathway help to trigger the disease,” said Small. The findings appeared in the Proceedings of the National Academy of Sciences.
http://www.thehindu.com/sci-tech/science/article642862.ece
Subscribe to:
Posts (Atom)